CoChat

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 35 of the 93 sources its claims cite were checked for support.

Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control

Open access
Lee, Young-Sun, Jun, Hee-Sook · 2016 · Mediators of Inflammation

Abstract

Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, reducing food intake, and stimulating glucose disposal. Therefore, GLP-1-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4, which is a GLP-1 inactivating enzyme, have been developed for treatment of type 2 diabetes. In addition to glucose-lowering effects, emerging data suggests that GLP-1-based therapies also show anti-inflammatory effects in chronic inflammatory diseases including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis. This review outlines the anti-inflammatory actions of GLP-1-based therapies on diseases associated with chronic inflammation in vivo and in vitro, and their molecular mechanisms of anti-inflammatory action.

Overview

CoChat Summary

## TL;DR

This review argues that GLP-1-based therapies have anti-inflammatory effects beyond glucose lowering, with evidence across diabetes, vascular disease, brain disorders, liver disease, nephropathy, and other inflammatory conditions. It summarizes in vitro, animal, and some human findings showing reductions in inflammatory cytokines, immune-cell infiltration, and related signaling pathways.

## Key findings

  • In diabetes, GLP-1-based therapies reduced inflammatory mediators in islets and adipose tissue: liraglutide (100 nM) inhibited palmitate-induced TNF-α, IL-1β, and IL-6 in mouse islets; sitagliptin (100 mg/day) reduced plasma CRP, IL-6, IL-18, secreted phospholipase-A2, soluble ICAM-1, and E-selectin in type 2 diabetes patients, while the inflammatory score and HOMA index for insulin resistance were also significantly reduced.
  • In vascular disease, liraglutide reduced adhesion molecules in endothelial cells and exendin-4 reduced atherosclerosis in mice; for example, exendin-4 (50 μg/kg/day) reduced atherosclerosis development and monocyte adhesion in APOE*3-Leiden.CETP mice, and sitagliptin reduced plaque macrophage infiltration and MMP-9 in ApoE−/− mice.
  • In neurodegenerative disease models, liraglutide reduced activated microglia and inflammatory responses in Alzheimer’s disease models, and exendin-4 (10 μg/kg) decreased MPTP-induced microglial activation and TNF-α/IL-1β in Parkinson’s disease models.
  • In other conditions, liraglutide improved asthma-related inflammation (including lower E-selectin, TNF-α, IL-4, IL-5, and IL-13) and exenatide improved sperm quality in diet-induced obese mice by suppressing testicular TNF-α, MCP-1, and F4/80.

## Methods

  • Narrative review of published in vivo and in vitro studies on GLP-1, GLP-1 receptor agonists, and DPP-4 inhibitors across inflammatory diseases.
  • Evidence base includes cell models, rodent and other animal models, and selected human studies (for example, patients with type 2 diabetes and nonalcoholic steatohepatitis).
  • Main analysis was qualitative synthesis of anti-inflammatory effects and molecular mechanisms, organized by disease area and signaling pathways.

## Limitations

  • The paper states that some reported benefits “need to be validated by clinical studies” for asthma, and that the safety of GLP-1-based therapy should be validated by “sufficient further studies” because rare cases of acute pancreatitis and neoplasms have been reported.
  • Evident from the text: this is a review, so many conclusions are based on preclinical or small clinical studies rather than a single controlled synthesis or meta-analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1155/2016/3094642

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Molecular signals underlying the anti-inflammatory effects of GLP-1-based drugs. DPP-4 inhibitors increase GLP-1 levels in plasma. GLP-1 and GLP-1 receptor (GLP-1R) agonists bind to the GLP-1 receptor, which blocks PKC or NF-κB activation and subsequent expression of NLRP3, IL-1β, TNF-α, IL-6, VCAM-1, IFN-γ, and MCP-1. In addition, GLP-1R signaling activates cAMP/Ca2+, CAMKKβ, and pAMPK, which induces anti-inflammatory effects on monocyte adhesion.
Figure 1 Molecular signals underlying the anti-inflammatory effects of GLP-1-based drugs. DPP-4 inhibitors increase GLP-1 levels in plasma. GLP-1 and GLP-1 receptor (GLP-1R) agonists bind to the GLP-1 receptor, which blocks PKC or NF-κB activation and subsequent expression of NLRP3, IL-1β, TNF-α, IL-6, VCAM-1, IFN-γ, and MCP-1. In addition, GLP-1R signaling activates cAMP/Ca2+, CAMKKβ, and pAMPK, which induces anti-inflammatory effects on monocyte adhesion.CC BY · PubMed Central
Figure 2 GLP-1-based therapies, including GLP-1, GLP-1R agonists and DPP-4 inhibitors, have anti-inflammatory functions in several organs.
Figure 2 GLP-1-based therapies, including GLP-1, GLP-1R agonists and DPP-4 inhibitors, have anti-inflammatory functions in several organs.CC BY · PubMed Central

Verification

Claims the paper makes

26 Valid · 0 Not valid · 23 Not checked · 23 Own results and interpretations

47 more claims · 13 with their cited sources checked

Create a free account to see all 72 claims and to verify the 6 references still open.

See all claims — free account
  • It may state two separate claims as one. 20

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 116 references

Cited by

See all 530

Metadata

Authors
Lee, Y.-S., & Jun, H.-S.
Affiliations
Gachon University (KR)
Corresponding author
Jun, Hee-Sook
Venue
Mediators of Inflammation
Publisher
Wiley
Published
2016
Volume
2016
Pages
1-11
ISSN
  • 0962-9351 (ISSN-L)
  • 1466-1861
OpenAlex
W2306319461
Cited by
530
References
116
Citations by year
2026: 68 · 2025: 83 · 2024: 56 · 2023: 52 · 2022: 60 · 2021: 72 · 2020: 53 · 2019: 47 · 2018: 21 · 2017: 15 · 2016: 3
FWCI
3.59
Type
journal article
Language
en
Open access
Locations
  • Mediators of Inflammation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Research Foundation of Korea (2015R1D1A1A01060232)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, DPP-4 inhibitors, anti-inflammatory activity, chronic inflammation, type 2 diabetes, type 1 diabetes, atherosclerosis, neurodegenerative diseases, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, psoriasis, glucose homeostasis, molecular mechanisms of inflammation
MeSH terms
Animals, Anti-Inflammatory Agents, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Inflammation, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. https://app.cochat.ai/papers/10.1155/2016/3094642
The paper
Lee, Y.-S., & Jun, H.-S. (2016). Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. Mediators of Inflammation. https://doi.org/10.1155/2016/3094642

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.